

Press release

At THRPTX (The THeRaPeuTics Innovation Summit), Servier reaffirmed its commitment to more agile research, which is more open and more patient-focused.

Suresnes, 1st July 2024 - For the first time, on 18 June last, Servier brought together global R&D players at its Paris-Saclay site to exchange on the latest therapeutic and societal progress in oncology. **A genuine catalyst of scientific progress, this original meeting is designed to be an unprecedented place of dialogue** on health research. The shared objective is to **steer sustainable innovation for the benefit of patients**.

“Sharing science and knowledge to make progress in medicine is part of the mission of Servier, governed by a foundation and present at each stage of the medicinal product value chain, from research and diagnostics to patient treatment and follow-up. With THRPTX, we aim to create an international meeting designed to improve knowledge and access to care services of the future for the benefit of patients.” **underlined Olivier Laureau, President of Servier**

During the interactive debates and roundtables, internationally renowned participants from the academic world, research, patient groups and the pharmaceutical industry underlined **the importance of a holistic and pluri-disciplinary approach to rise to the major challenges in oncology**. Among the challenges, we can notably mention the development of targeted therapies on the molecular profile of patients, the fight against treatment resistance mechanisms and optimum exploitation of progress in disruptive technologies.

“Only a collaborative and pluri-disciplinary approach will enable us to rise to the challenges in oncology. THRPTX illustrates the desire for open and constructive dialogue with all stakeholders to accelerate the emergence of innovative, accessible and sustainable therapeutic solutions” **concluded Claude Bertrand, Executive VP Research & Development at Servier**.

The patient at the heart of the debate on the future of therapeutic innovation

With one in two people suffering from cancer during their lifetime, and the number of new cases of cancer set to increase by 77% between 2022 and 2050 according to the WHO, Servier has chosen to focus this first THRPTX Innovation Summit on oncology. A priority for the Group which is reflected in devoting 70% of its R&D budget to research on therapies for difficult to treat cancers.

First major focus of exchanges: **each patient is unique. While obvious, this raises major challenges for research. Experts have called for better integration of patients** in early innovation stages, both for research and for healthcare protocols. They also called for greater cooperation between all health players to **evolve towards ever-more personalised and efficient medicine**. An objective summed up during the debates: *“the right medicinal product for the right patient, with the right dosage at the right time”*.

Among the levers identified:

- Taking account of the differences between individuals, in particular in terms of clinical trials where certain categories of the population are still under-represented;
- Integration of patients earlier and earlier in protocols for a significant impact in the fight against cancer and to move from a curative treatment strategy to a prevention strategy;
- The engagement and mobilisation of patients in the development of therapies, notably by calling on patient communities to foster a co-creation dynamic and make them active players and drivers of research;
- Development of personalised vaccination therapy, which has demonstrated its efficacy in oncology and is still only in its infancy.

Lastly, THRPTX underlined the **unique momentum in which we find ourselves: a situation where tools and technology exists and enable us to consider oncology clinical research differently.** Reflection that inspired hope of an acceleration in the scientific discoveries of tomorrow.

Accelerating innovation and research in oncology: the need to share information

Faced with the huge amount of data potentially available, the challenge now consists in being able to process and integrate this data to assist healthcare professionals. Whether it is to better understand the disease and how it progresses in patients, or to identify patient-targeted action mechanisms or patient-group actions, **data analysis including AI, are significant and extremely efficient tools** to facilitate decision making, make research more agile and capture the unexpected. Indeed, AI action levers are numerous: promoting early diagnostics, accelerating the development of new molecules, enhancing patient care by identifying potential complications and providing the right monitoring tools for better observance.

Expectations of patients and society are high in terms of innovation. Whether regarding healthcare access pathways, accelerating research or data protection... Faced with these high expectations, the debates between experts at THRPTX enabled the discovery of **the need for information, training and education of the public.** To improve therapeutic adherence, in other words treatment observance, it is important to help the public better understand what innovation is, what the stakes involved in research are and what precisely is the current state of play in terms of therapeutic progress. To achieve this, and now more than ever in this post-Covid society, the way that scientists, researchers and laboratories exchange, share and discuss their work is key.

Evoked during the exchanges, **the notion of the value of treatments is essential.** For the experts present at THRPTX, inspired by the “value-based healthcare” concept, value must go beyond the notion of overall survival and also take account of the impact of treatments on the daily lives of patients, on society, on the sustainability of healthcare systems and even on the environment. All of these aspects **require greater cooperation between players in the health sector, as desired and implemented at the Servier’s first THeRaPeuTics Innovation Summit.**

To discover the highlights of Servier’s first THeRaPeuTics Innovation Summit (THRPTX), go to the site: <https://servier.com/en/newsroom/thrptx-innovation-summit-symposium>

Press contacts

Servier

Marion Breyer marion.breyer@servier.com
Presse@servier.com

Havas Red Health

Juliette Arcos-Desloges
juliette.desloges@havasred.com
Claire Olivieri
claire.olivieri-ringot@havasred.com

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier’s ambition is to become a focused and innovative player in oncology by targeting rare cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.3 billion in 2023.

More information on the new Group website: servier.com

Follow us on social media: : [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)